The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)
Abstract
Background Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the posterior pole that are characterized by macular edema and/or intraocular neovascularization. Recently anti-VEGF agents such as ranibizumab and pegaptanib sodium have been shown to be beneficial in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). However in most parts of the world, both pegaptanib sodium and ranibizumab are not readily available. Bevacizumab, a humanized recombinant monoclonal IgG antibody that binds and inhibits all VEGF isoforms, has been proposed as an alternative treatment option.Methods A total of 1,265 consecutive patients were injected with bevacizumab for diseases such as proliferative diabetic retinopathy, diabetic macular edema, retinal vein occlusions, and CNV of several etiologies including ARMD at eight Latin American institutions from 1 September 2005 to 31 January 2006. Of these 1,265, 92 were excluded because they were injected once and lost to follow-up. The remaining 1,173 patients constitute the subjects of this retrospective, multicenter, open label, uncontrolled interventional case series that reports the cumulative systemic and ocular adverse events following intravitreal bevacizumab during 12 months of follow-up. Patients were examined at baseline and then monthly. If the patients were unable to attend the 12-month visit, a telephone interview was conducted to assess for possible systemic complications.Results A total of 4,303 intravitreal injections of bevacizumab on 1,310 eyes was reported. All 1,173 patients were accounted for at the 12-month visit. Systemic adverse events were reported in 18 (1.5%) patients. These included seven (0.59%) cases of an acute elevation of systemic blood pressure, six (0.5%) cerebrovascular accidents, five (0.4%) myocardial infarctions, two (0.17%) iliac artery aneurysms, two (0.17%) toe amputations and five (0.4%) deaths. Ocular complications included seven (0.16%) bacterial endophthalmitis, seven (0.16%) tractional retinal detachments, four (0.09%) uveitis, and a case (0.02%) each of rhegmatogenous retinal detachment and vitreous hemorrhage.Conclusion Despite the limited follow-up, repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bevacizumab has been shown to have an incidence of sterile inflammation between 0.09% and 1.1% according to several retrospective studies [16, 27, 28].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [28]
In the citing paper
“In addition, the formulation in which the drug is administered has previously been shown to induce an inflammatory response.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [28]
In the citing paper
“Initial studies on ranibizumab showed an 11.4% inflammation rate, which drastically improved after reformulating the drug from a lyophilized formulation to a solubilized formulation [28, 51].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [28]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 4×
“In addition systemic hypertension was seen in a fair number of patients [8].”
BackgroundInfluentialPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 3×
“Recently pegaptanib sodium (Macugen®, Eyetech, NY, NY), an aptamer against VEGF165, has been shown to be beneficial in the treatment of CNV secondary to age-related macular degeneration (ARMD) and DME [5, 6].”
Background(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133 · cited 1×
“Other smaller series have also confimed a lack of systemic complications following an intravitreal injection of 1.25 mg of bevacizumab [20, 21 ].”
BackgroundInfluentialRosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904 · cited 2×
“Intraocular inflammation has been shown to be the doselimiting toxicity of intravitreal ranibizumab [11].”
Background(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Bressler, N. M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01237-5 · Cited by 666
MICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664 · cited 2×
“A mild transient, but significant elevation in mean systolic blood pressure was reported in patients with CNV secondary to ARMD who received a systemic infusion of bevacizumab [9].”
BackgroundSPAIDE, R. F., LAUD, K., FINE, H. F., KLANCNIK, J. M., MEYERLE, C. B., YANNUZZI, L. A., SORENSON, J., SLAKTER, J., FISHER, Y. L., & COONEY, M. J. (2006) · Retina · doi:10.1097/00006982-200604000-00001 · Cited by 630 · cited 1×
“Other smaller series have also confimed a lack of systemic complications following an intravitreal injection of 1.25 mg of bevacizumab [ 20 , 21].”
BackgroundInfluential(2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.06.007 · Cited by 594 · cited 2×
“Recently pegaptanib sodium (Macugen®, Eyetech, NY, NY), an aptamer against VEGF165, has been shown to be beneficial in the treatment of CNV secondary to age-related macular degeneration (ARMD) and DME [5, 6].”
Background
Cited by
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
Mccannel, C. A. (2011) · Retina · doi:10.1097/iae.0b013e31820a67e4 · Cited by 397
“Studies reporting endophthalmitis and causative organisms after intravitreal injection outside the United States were reports by Aggio et al,(21) Alkuraya et al,(22) Artunay et al,(23) and Yenerel et al,(24) and Wu et al.(25) A report by Lee et al(26) was excluded because the authors convincingly tracked the occurrenc…”
BackgroundAge-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 349
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304
Metadata
- Authors
- Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES)
- Affiliations
- University of Puerto Rico System (PR)
- Universidade Federal de São Paulo (BR)
- Corresponding author
- Wu, Lihteh
- Venue
- Graefe's Archive for Clinical and Experimental Ophthalmology
- Published
- 2007-08-03
- Volume
- 246
- Issue
- 1
- Pages
- 81-87
- ISSN
- 0721-832X (ISSN-L)
- 1435-702X
- OpenAlex
- W2029119558
- Cited by
- 456
- References
- 34
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 12 · 2021: 12 · 2020: 14 · 2019: 15 · 2018: 13 · 2017: 23 · 2016: 18 · 2015: 25 · 2014: 35 · 2013: 40 · 2012: 37
- FWCI
- 43.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Graefe s Archive for Clinical and Experimental Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- bevacizumab, intravitreal injection, drug safety, adverse events, choroidal neovascularization, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, anti-VEGF therapy, bacterial endophthalmitis, vitreous hemorrhage, retinal detachment, systemic hypertension, stroke
- MeSH terms
- Bevacizumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Diabetic Retinopathy, Female, Humans, Injections, Macular Degeneration, Macular Edema, Male, Middle Aged, Retinal Vein Occlusion, Retrospective Studies, Time Factors, Visual Acuity, Vitreous Body, Treatment Outcome, Retreatment, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). https://app.cochat.ai/papers/10.1007/s00417-007-0660-z
- The paper
- Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES). (2007). Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-007-0660-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.